Benedetti & Gucer’s Novo Nordisk NVO Stock Holding History

Benedetti & Gucer’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,244	Closed	-$232K	–	149
2023 Q4	$232K	Buy	+2,244	New	+$222K	0.12%	119

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Benedetti & Gucer's NVO Position: Q1 2024 in Review

Benedetti & Gucer sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 2,244 shares — an estimated $232K sold.

Benedetti & Gucer first reported a position in NVO in Q4 2023 and held it in 1 quarter. The position peaked at $232K in Q4 2023. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

Benedetti & Gucer reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
Benedetti & Gucer sold 2,244 Novo Nordisk shares in Q1 2024, an estimated $232K.
Benedetti & Gucer first reported a position in Novo Nordisk in Q4 2023 and held it in 1 quarter.
Benedetti & Gucer's Novo Nordisk position peaked at $232K in Q4 2023.
1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Benedetti & Gucer's 13F filing for Q1 2024, filed 7 May 2024.